Pfizer Reports Sutent Safe And Effective In Asians, Forges Alliances With Major Asian Oncology Centers
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer may draw on Sutent research centers for trials on other oncology therapies such as axitinib and figitumumab, an insulin growth factor receptor inhibitor.